Patents Assigned to Canget BioTekpharma, LLC
  • USE OF THE FL-ONE HUNDRED EIGHTEEN CORE CHEMICAL STRUCTURE PLATFORM TO GENERATE FL-ONE HUNDRED EIGHTEEN DERIVATIVES FOR TREATMENT OF HUMAN DISEASE
    Publication number: 20180170944
    Abstract: Described herein, are FL118 core structure platform compounds, matter of compositions, formulation, methods and uses for treating cancer or other human diseases. Chemical modifications of the FL118 structure are employed alone or in combination with other anti-cancer agents to preclude or reverse refractory cancer phenotypes and for unique personalized cancer treatment (personalized medicine or as Obama called precision medicine) through application of a series of structural relevant individual FL118 platform-derived analogues.
    Type: Application
    Filed: March 24, 2015
    Publication date: June 21, 2018
    Applicant: Canget BioTekpharma, LLC
    Inventors: Fengzhi LI, Xiang LING